Elias Mossialos: The politics of R&DBMJ 2017; 358 doi: https://doi.org/10.1136/bmj.j3756 (Published 16 August 2017) Cite this as: BMJ 2017;358:j3756
Elias Mossialos, 56, is professor of health policy at the London School of Economics (LSE) and Imperial College London, inaugural head of LSE’s new department of health policy, and founder and director of LSE Health, a research centre with 60 staff that last year won a major role in a pan-European project on using big data to improve health outcomes. He has developed the Options Market for Antibiotics, an incentive scheme to stimulate research and development (R&D), and his recent research on cancer drugs found that one in three licensed in 2003-13 produced no overall survival benefit. Unusually for an academic policy expert, Mossialos has experience at the sharp end, having served as minister of state for the Greek government of George Papandreou in 2011.
What was your earliest ambition?
To study economics and politics. I ended up doing medicine first, but I eventually came back to them …